Impact of Human Papillomavirus Carriage on IVF/ICSI Results (HPV AMP)

Phase

N/A

Condition

Infertility

Treatment

N/A

Clinical Study ID

NCT06550531

29BRC21.0363 - HPV AMP

Ages 25-38
Female

Study Summary

The prevalence of the papilloma virus in the general population is 12%. This virus is known to impair male fertility but its impact on female infertility remains uncertain. This is a public health problem since there is a vaccination protocol. Demonstrating the impact of the human papillomavirus on fertility would be an argument in favor of vaccination.

Eligibility Criteria

Inclusion

Inclusion Criteria:

all etiology of infertility AMH > ou = à 1.1 ng/ml First ou second protocol of IVFbetween 25 years and 37 years and 11 months

Exclusion

Exclusion Criteria:

Age < 25 y Age > ou = 38 y AMH < 1.1 ng/ml patient under juridic protection rejection of participation

Study Design

February 04, 2022

February 04, 2026

Study Description

This is a single-center prospective study in the assisted reproduction center of Brest University Hospital. All new patients coming to consult will be offered participation in the study. The HPV test will be updated if it is older than 12 months. We will analyze stimulation results and pregnancy outcomes according to HPV status. Inclusions will take place over 3 years

Connect with a study center

CHRU de Brest
Brest, 29609
France
Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.